Displaying drugs 10151 - 10175 of 12439 in total
Fenproporex
Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency....
Experimental
Illicit
Withdrawn
Matched Description: … efficacy and safety data, and is listed as a drug in Schedule IV of the Controlled Substances Act. ... fenproporex (N-2-cyanoethylamphetamine) falls within the phenylethamine and amphetamine chemical class of ... Contrary to the claim, research has demonstrated easy in vivo cleavage of the N-2-cyanothyl substituent …
Brotizolam
Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent...
Investigational
Withdrawn
Matched Description: … Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. ... Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 …
PS386113
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders …
Mepiprazole
Mepiprazole is a minor tranquilizer with a phenylpiperazine structure. It is a pyrazolyl-alkyl-piperazine derivative. Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons .
Mepiprazole is marketed in Spain for the treatment of anxiety neuroses.
It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and...
Experimental
Matched Description: … Mepiprazole is marketed in Spain for the treatment of anxiety neuroses. ... Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816]. ... Clinical studies of mepiprazole including patients with irritable bowel syndrome (IBS) were conducted …
Aptazapine
Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine. Although Aptazapine reached clinical trials, it...
Experimental
Matched Description: … effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of …
Isatoribine
Isatoribine is a selective agonist of TLR7.
Investigational
Matched Description: … Isatoribine is a selective agonist of TLR7. …
Tideglusib
Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia...
Investigational
Withdrawn
Matched Description: … Alzheimer's disease as of 2012. ... Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for ... reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of …
AZD0947
AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Investigational
Matched Description: … As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared ... AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive …
Lesopitron
Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
Investigational
LGD2941
LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
Investigational
Sitimagene ceradenovec
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.
Investigational
Matched Description: … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high ... grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy …
Forasartan
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in...
Experimental
Matched Description: … , blockage of its effects results in a decreases in systemic vascular resistance. ... As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone …
ReN001
ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the...
Investigational
Matched Description: … ReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable ... ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food ... and Drug Administration in the United States for consideration for the treatment of stroke in humans …
8-chlorotheophylline
8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine. Its main use is in combination with Diphenhydramine as the antiemetic drug Dimenhydrinate. The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous...
Experimental
Matched Description: … 8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar ... anti-histamine activity in the central nervous system.
8-chlorotheophylline produces a number of ... Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the …
Tenocyclidine
Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Experimental
Illicit
Investigational
Tirapazamine
Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia. Hence, tirapazamine is solely activated in those hypoxic areas of solid...
Investigational
Matched Description: … Hence, tirapazamine is solely activated in those hypoxic areas of solid tumors. ... For all these reasons, the combination of tirapazamine with other anticancer treatments is highly recommended …
Adinazolam
Adinazolam (Deracyn®) is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was first developed to enhance the antidepressant effects of alprazolam. It has never been approved by the FDA for clinical use.
Experimental
Matched Description: … Adinazolam was first developed to enhance the antidepressant effects of [alprazolam]. …
Pexelizumab
Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
Investigational
PH94B
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Matched Description: … It is a member of a new family of pharmaceutical compounds called vomeropherins. ... PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized …
BTA9881
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
APD791
APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Investigational
Matched Description: … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet …
Captodiame
Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.
Experimental
Matched Description: … It is a derivative of diphenhydramine. …
NRP409
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Setiptiline
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … In Japan, the company Mochida started its commercialization for the treatment of depression started in …
Displaying drugs 10151 - 10175 of 12439 in total